Ask AI
HER2 Biology and Testing in GI, GU, and GYN

CME

HER2: Biology and Testing in Gastrointestinal, Genitourinary, and Gynecologic Malignancies

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: August 04, 2025

Expiration: February 03, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following actionable HER2 alterations is most frequently identified across genitourinary (GU), gastrointestinal (GI), and gynecologic (GYN) cancers? 

2.

Why is it important to distinguish between HER2 amplification, overexpression, and mutation?

3.

Based on current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines, which of the following results would be considered HER2-positive?